₹457 Crore Revenue, ₹37 Crore Profit — The Margin Recovery Thesis Starts Here
Harsha delivered 25% revenue growth but flat profit, pivoting management guidance lower on raw material pass-through lag. The call reveals why the street sold off day-1, and what it will take to believe the margin rebound.
₹457.4 Cr
+25.2% YoY
₹37.4 Cr
-1.5% YoY
15.9%
−150 bps YoY
21% YoY
6% QoQ
The gap between this quarter's topline and bottom line is the entire story. Harsha's revenue engine is firing—25% consolidated growth, 21% in the core India engineering segment, and 35% in bushing. But net profit barely moved. On the call, management downgraded the year-ahead margin band from 24% (Q1 standalone) to 20–22%, citing 8% raw material cost inflation and a 1–2 quarter lag before customer price acceptance kicks in. The street's -2.08% day-1 sell-off was not overreaction; it was the market repricing the company from a "growth inflects profit" narrative to a "grow into margin compression" one.
Where the profit compression came from
EBITDA fell 150 basis points year-over-year—to 15.9% from 17.4%—despite 25% revenue growth. Two factors explain it. First, raw material prices (brass, copper, zinc, steel, polymer) rose 8% globally; the company operates on indexed pricing with a 1–2 quarter lag, so Q1 bore the cost inflation before customer passes-through became visible. Second, a ₹4 crore FX hedge loss on Romania operations masked an otherwise stronger operating result. Together, these created the arithmetic: revenue up 25%, EBITDA margin down 150 bps, and profit down 1.5%. Management is confident the RM pass-through will normalize margins by H2 FY27, but that depends on customer acceptance and competitive dynamics—neither guaranteed.
Satisfactory Q1 performance in line with management plan
OverstatedRevenue +25% YoY beat guidance; PAT −1.5% despite topline growth missed margin expectations
Pass-through of 8% RM increase will normalize margins in Q2
PartialOPM fell 150 bps YoY; pass-through timing unverified, depends on customer acceptance and competitive dynamics
Strong 21% growth in India Engineering with 6% QoQ growth
SupportedConfirmed; India segment delivered exactly 21% YoY and 6% QoQ despite macro headwinds
Bushing targeting 30% growth FY27 with strong visibility
SupportedQ1 delivered 35% YoY; order book and pipeline assurances backed by new product pipeline (wind, EV)
Advantek ₹140 Cr+ revenue target for FY27
ContradictedQ1 ₹30 Cr, FY26 ₹43 Cr; requires ₹35 Cr/qtr run-rate from current ₹30 Cr over 9 months—3.25x growth highly aggressive
What changed on this call
India growth guidance upgraded: mid-teens → high-teens (16%+ support)
Japan customer downgraded: 25% Q1 growth but guiding only 10% FY27 (₹80 Cr); slow project pipeline
Margin band narrowed: 24% Q1 standalone → 20–22% FY27 guidance (RM costs + capex ramp)
Romania losses timeline pushed: 'gradual reduction' to ₹2–3 Cr by FY27 end; breakeven now 'maybe next year'
The market's take
On day 1, the stock fell 2.08% with heavy delivery (84.5%), signaling institutional selling. By day 3, it recovered only +0.44%—a clear verdict that the market doesn't believe the RM pass-through thesis yet. At ₹412.25, the stock is 12.1% below its all-time high of ₹469, trading below its 50-day moving average (₹416.39) but above its 200-day (₹389.38). Volume has increased, but momentum remains neutral (RSI 53.3). FII ownership trimmed 0.58 percentage points in Q1 (now 1.79%), while domestic institutions added 0.59 percentage points (now 13.02%), suggesting foreign investors are skeptical of the margin recovery narrative while DIIs are buying the capex thesis. The street is right to wait: until Q2 shows RM pass-through visibly restoring EBITDA margin toward 18%+, the stock deserves to trade in the ₹390–₹420 range, not back toward the highs.
The bull-bear ledger
25% consolidated revenue growth; 21% India segment growth despite macro headwinds
Bushing +35% YoY; Stamping +31% YoY; new product pipeline (wind gearbox, rails, aerospace, EV) credible
India export ₹139 Cr (+22% YoY); broad-based global demand across Europe, US, bearing OEMs
CapEx execution on track: Bhayla Phase-2 construction rolling; China brownfield Q3 FY28 commissioning
PAT flat (−1.5%) despite 25% topline growth; margin compression unresolved, not a temporary cost spike
Margin guidance walked down: 24% → 20–22%; recovery depends on customer acceptance of price hikes (unproven)
Advantek needs 3.25x growth in 9 months to hit ₹140 Cr; PAT positive by FY27-end unverified
Romania continues loss-making despite topline growth; breakeven timeline pushed to 'maybe FY28'; combined China + Romania loss ₹6 Cr still
Japan customer guidance downgraded to 10% FY27 despite 25% Q1 growth; project pipeline described as 'very slow'
Large-size Cages only ₹10 Cr in Q1 vs 50% FY27 growth target; new facility ramping slower than expected
Risks, ranked by how much they should concern a holder
RM cost pass-through acceptance & timing
High8% material cost increase is pending 1–2 quarter lag. If customers resist price hikes or competitive dynamics prevent full pass-through, margin recovery extends beyond H2 FY27. OPM down 150 bps YoY is structural, not cyclical.
Advantek ramp-up execution
High₹140 Cr FY27 target requires ₹35 Cr/qtr run-rate starting Q2; Q1 was only ₹30 Cr. PAT positive by FY27-end is unproven. Any stumble in new customer wins or product adoption derails the target and compounds margin dilution.
Romania profitability path unclear
HighCombined China + Romania loss ₹6 Cr in FY26; guiding ₹2–3 Cr by FY27-end. Q1 saw ₹2 Cr FX loss on Romania, masking operational issues. Management hedged with 'gradually reduce losses' and 'maybe next year' breakeven—precision is absent.
Large-size Cages ramp slowness
MediumQ1 only ₹10 Cr vs 50% FY27 growth target (implying ₹50 Cr+ revenue). New facility underutilized; if ramp delays persist, the high-value segment becomes a drag on consolidated margin recovery.
Japan customer deceleration
MediumQ1 ₹21 Cr (+25% YoY) but FY27 guidance only 10% (₹80 Cr). Slow project pipeline acknowledged. If new projects don't materialize, the segment underperforms and reduces consolidated revenue visibility.
The debate
What to watch next
1 · Q2 FY27 EBITDA margin recovery (October 2026)
This is the linchpin. If India segment EBITDA margin rebounds to 22%+ in Q2, the RM pass-through narrative holds and margin recovery is underway. If it stays 19–20%, customers are resisting price hikes and the bear case (margin compression structural) has teeth. Watch consolidated EBITDA margin; if it's 17%+, the pass-through is working.
2 · Advantek sequential ramp (Q2 & Q3 FY27)
Q1 was ₹30 Cr; Q2 needs to be ₹32+ Cr and Q3 ₹35+ Cr to reach the ₹140 Cr FY27 target. If Advantek stalls at ₹30–31 Cr/qtr, the 3.25x growth target is at risk, and PAT positive by FY27-end becomes unlikely. EBITDA margin at Advantek (management guided 9% in Q1) is also critical; if it stays 8–10%, the subsidiary remains a dilutant.
3 · Romania + China loss trajectory (H2 FY27)
Management guided ₹2–3 Cr combined loss by FY27-end (vs ₹6 Cr in Q1). If H2 shows losses narrowing materially, the turnaround narrative gains credibility. If combined losses stay ₹5+ Cr, the subsidiary drag persists and the bull case weakens.
This is steady execution, not a step-change. Harsha is growing revenue and scaling capex on time, but margin recovery is uncertain and execution risk is real. The stock deserves to trade below the ₹430–₹469 range (near-term highs) until Q2 proves the RM pass-through is working. The single number to track from here is India segment EBITDA margin in Q2; if it's 22%+, the bull case re-rates and the stock moves back toward ₹420+. If it's 20% or lower, the market's skepticism is justified and the stock stays range-bound. Hold for the capex upside (FY28–29), but don't chase the near-term margin recovery story until it's visible.
Informational and educational content only. Not investment advice.